Osiris Therapeutics, Inc. Receives FDA Clearance to Broaden Prochymal Expanded Access Program

COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced U.S. Food and Drug Administration (FDA) clearance to broaden its expanded access program (EAP) for Prochymal, now making the investigational stem cell product available to adults with life-threatening Graft vs. Host Disease (GvHD). In May of 2008, FDA approved the first Prochymal EAP for the treatment of pediatric GvHD patients.